Object. Whole-brain radiation therapy (WBRT), open resection, and stereotactic radiosurgery (SRS) are widely used for treatment of metastatic brain lesions, and many physicians recommend WBRT for multiple brain metastases. However, WBRT can be performed only once per patient, with rare exceptions. Some patients may require SRS for multiple metastatic brain lesions, particularly those patients harboring more than 10 lesions. In this paper, treatment results of SRS for brain metastasis were analyzed, and an attempt was made to determine whether SRS is effective, even in cases involving multiple metastatic brain lesions.
B
rain metastases occur in 20%-40% of patients with cancer and are generally associated with a poor prognosis. 18, 24 However, the incidence of brain metastases has been increasing due to the growing population and prolongation of life expectancy in patients with cancer due to evolving systemic treatments. The prolonged survival of patients after diagnosis of primary cancer and early detection of brain metastases also increases the incidence of recurrent brain metastases. Whole-brain radiation therapy has long been a standard treatment for patients with brain metastases. However, it is generally known that WBRT alone is not sufficient, given its outcome is a short median duration of survival, regardless of the type of primary lesion, with the exception of small cell lung cancer. 9, 19 Another alternative, radiosurgery, currently is playing a greater, more important role in the management of metastatic brain tumors.
Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?
Whole-brain radiation therapy should be deferred as long as possible. We need additional treatment options for recurrent brain metastases and should be concerned about the early and delayed treatment-related complications of WBRT. The timing of each treatment modality should be a more important issue than its relative superiority. The number of metastatic brain lesions is another important factor to consider when selecting a treatment modality. Despite the fact that what constitutes a reasonable number of brain lesions for each treatment modality is still under debate, patients with multiple metastatic brain lesions usually receive WBRT. However, there are cases in which multiple brain metastatic lesions should be treated with SRS alone, specifically in patients who previously have undergone WBRT, patients who need urgent therapy for systemic disease control, and patients who have a diagnosis of a single metastasis or oligometastasis in the brain on diagnostic MR images with newly detected lesions on MR images obtained on the day of radiosurgery.
In this study, we analyzed overall survival time, local control rate, and the probability of newly developed metastatic lesions in the brain following treatment with SRS alone in patients with multiple brain metastatic lesions.
Methods
Between October 2005 and October 2008, 323 patients underwent SRS for the first time for metastatic brain lesions at our hospital. Stereotactic radiosurgery was performed using the Gamma Knife model C or Perfexion (Elekta AB). Patients were referred for radiosurgery after having already undergone a complete systemic workup. If they survived, they were observed for more than 12 months. Patients with a Karnofsky Performance Scale score < 70 and those with a Recursive Partitioning Analysis Class III were excluded from the present study. 8 In all patients, T1-weighted MR images with and without addition of gadibutrol (Gadivist, Bayer Schering Pharma AG) and T2-weighted MR images with 1-mm slices were obtained after a Leksell G frame had been affixed to the head. After SRS, MR imaging studies were repeated every 3 months if the patient's condition allowed, until the brain lesions were completely resolved or the patient died. All clinical and imaging data were retrospectively reviewed. Local tumor control was defined as a tumor that had decreased or remained stable in size, and tumor progression was defined as an increase in the size of a previously controlled tumor at the final follow-up. Radiation-induced change was defined as an increase in peritumoral edema, with decreased relative cerebral blood volume shown on perfusion MR imaging without an increase in the size of the tumor enhancement. Remote tumor progression was defined as a new metastasis elsewhere in the brain.
The patients were divided into 4 groups according to the number of brain lesions visible on stereotactic MR imaging: Group 1, 1-5 lesions; Group 2, 6-10 lesions: Group 3, 11-15 lesions; and Group 4, > 15 lesions. The patients' overall survival time and curve, local control rate, probability of developing new lesions at a distant area of the brain, and existence of radiation necrosis were evaluated and compared in each group.
All statistical tests were 2-tailed, and statistical significance was indicated by a probability value less than 0.05. We used SPSS software (version 13.0, SPSS, Inc.) for statistical analysis.
Results
The patient population consisted of 172 men and 151 women. The patients' mean age at the time of SRS was 59 years (range 30-89 years). The mean follow-up duration was 6 months (range 0-44 months). Non-small cell lung cancer was the most common cause of metastatic brain tumor in this study, followed by breast cancer and renal cell cancer. According to the classification system we used, 215 patients (66.6%) belonged to Group 1, 58 patients (18.0%) to Group 2, 17 patients (5.3%) to Group 3, and 33 patients (10.2%) to Group 4 ( Table 1) .
The overall median survival time after SRS was 10 months (95% CI 8.7-11.4 months), and the median survival times of each group were as follows: Group 1, 10 months (95% CI 8.3-11.7 months); Group 2, 10 months (95% CI 5.9-14.1 months); Group 3, 13 months (95% CI 5.5-20.5 months); and Group 4, 8 months (95% CI 5.2-10.8 months). There was no statistical difference in survival times after SRS between groups (log-rank test, p = 0.554) ( Fig. 1 and Table 2 ).
The overall median progression-free survival time was 9 months (95% CI 6.5-11.5 months), and the median progression-free survival time in Group 4 was 6 months (95% CI 4.6-7.4 months), which was statistically shorter than that of the other groups (log-rank test, p = 0.028). The local tumor control rates were not statistically different between groups (log-rank test, p = 0.989), but remote progression was more frequent in Group 4 (log-rank test, p = 0.014) (Figs. 2 and 3; Table 2 ).
Among the 33 patients in Group 4, 14 patients (42.4%) underwent SRS for salvage treatment after previous WBRT. The remaining patients received SRS for other reasons, for example, requiring urgent therapy for systemic disease control or for newly found lesions on stereotactic MR imaging. Whether radiosurgery was performed up front or for salvage, the reason for performing SRS in Group 4 did not affect the median survival time (log-rank test, p = 0.921).
Radiation-induced change was observed on followup MR images in 23 patients (7.12%), only 1 of whom was in Group 4 (3.0%). This Group 4 patient had 16 metastatic brain lesions and underwent WBRT 10 months prior to SRS. Radiation-induced changes in Group 4 were not more numerous than those in other groups (Table 2) .
Discussion
The most common route of metastatic dissemination resulting in brain metastases is regarded to be hematogenous, and the entire brain is presumed to be "seeded" with micrometastatic disease, even when only a single intracranial lesion is detected. 18, 24 For this reason, WBRT has been considered as the gold-standard therapy for metastatic brain tumors. However, because the results of WBRT alone are generally poor, booster SRS is widely recommended to improve patient survival and functional autonomy, especially in patients with fewer than 5 brain metastases. 1, 9, 13, 15, 22 Early and delayed radiation-related complications are another weakness of WBRT, especially for a long-term survivor with cancer that has metastasized to the brain. One of the most severe adverse effects of WBRT is a dose-dependent deterioration in neurocognitive function caused by leukoencephalopathy, which can occur despite control of the brain tumor, an important factor for stabilizing neurocognitive function. 4, 7 Conversely, many authors have reported on the role of SRS for treating brain metastases in an attempt to determine whether WBRT could be omitted. One randomized case-control trial of 132 patients showed that patients with 1-4 metastatic brain tumors who underwent up-front WBRT after SRS did not have improved survival, despite the fact that they had a lower chance of remote disease progression. 3 Findings in many other reports also support the hypothesis that SRS combined with WBRT does not prolong survival in patients with metastatic brain tumors, especially in patients with fewer than 5 brain metastases. 11, 15, 16, 22, 23 Looking at all these viewpoints, it appears that both SRS and WBRT play important roles in the treatment of patients with fewer than 5 brain metastases, although the timing and sequence of these treatment modalities are debatable.
For the treatment of patients with more than 5 metastatic brain lesions, WBRT is widely used for improvements in signs and symptoms related to brain metastases. 5, 14, 25 However, a lack of radiosurgical results exists for patients with more than 5 metastatic brain lesions. Suzuki et al. 26 reported relatively favorable radiosurgical outcomes in patients with more than 10 metastatic brain lesions, including low incidence of morbidity, acceptable tumor control, and a good quality of life. The cumulative survival rates were 70.4%, 49.3%, and 12.3% at 12, 24, and 36 weeks, respectively. Shuto et al. 21 also insisted that the number of metastatic brain lesions did not affect a patient's survival, even in patients with more than 20 tumors. In this study, the survival rate of patients with more than 15 metastatic lesions was not statistically different from those of patients in other groups, although there was a tendency for decreased survival time. The cumulative * HCC = hepatocellular carcinoma; NSCLC = non-small cell lung cancer; RCC = renal cell cancer; SCLC = small cell lung cancer. † Unless otherwise specified. survival rates of Group 4 were 93.9%, 84.8%, and 72.7% at 3, 6, and 9 months, respectively. Compared with findings of other studies in which WBRT was evaluated for treatment of multiple brain metastases, the survival rate in our patients with more than 15 metastases appears to be good, even if this study was not a randomized or casecontrol study.
The progression-free survival time for Group 4 was statistically shorter than those for the other groups. Given that there was no statistical difference in the local control rate between Group 4 and Groups 1, 2, and 3, the cause of the shorter progression-free survival time for Group 4 could be mainly due to more frequent remote tumor progression. Several authors have reported similar findings regarding the correlation of remote progression and the number of metastatic lesions. 12 We hypothesize that this may be due to the biological properties of each metastatic lesion. Some tumors, even though they have the same pathological characteristics, do not metastasize to another site of the brain until growth of the first metastatic lesion induces neurological symptoms. However, other tumors metastasize to multiple sites of the brain simultaneously. It may be easier for the latter tumors to metastasize to the brain, and, if the primary tumor is not controlled, the chance of metastasis to the brain remains high.
Another factor involved in the finding of more frequent remote progression is imaging technology. Contrastenhanced MR imaging with a Gd-based contrast agent is widely considered the most accurate diagnostic imaging modality for the detection of cerebral metastases. 20, 27 We routinely use gadobutrol for stereotactic contrast-enhanced T1-weighted MR imaging, because gadobutrol offers advantages over gadopentetate dimeglumine for the visualization of brain metastases and for the detection of lesions.
2 However, gadobutrol is unable to detect all metastatic lesions, including microscopic metastases. Therefore, there are currently no imaging modalities capable of visualizing all metastatic lesions, although new technologies are currently being investigated, including the use of nanoparticles. 6, 17 In Group 4, a total of 19 patients (57.6%) had remote tumor progression. In 7 (36.8%) of these 19 patients, new brain metastatic lesions developed within 3 months after SRS. With improvements in imaging modalities, we expect that these lesions will be treated at the first SRS and not counted as remote progression (Fig. 4) .
A radiation-induced adverse effect is also a considerable factor to take into account when choosing the appropriate treatment modality. Yang et al. 29 reported that the maximum number of tumors that could be treated with SRS may be 25, if the masses are small and the maximum doses are less than 40 Gy. Other authors have suggested that SRS could be performed with acceptable radiationinduced complications for patients with more than 10 lesions. 10, 21, 28 In this study, the occurrence rate of radiationinduced imaging changes on follow-up MR images in Group 4 was not higher than the combined rate for the other groups (a total of 8.6% in Groups 1, 2, and 3 vs 3.0% in Group 4). In conclusion, when comparing these results with those of earlier reports, we do not recommend that the selection of the appropriate treatment modality be based merely on the number of brain lesions. Several factors should be considered together, including the status of the primary cancer; the patient's clinical and functional status; the size, location, number, and peritumoral edema of brain lesions; and the history of previous treatment.
This study had several limitations. First, this study is not a randomized or case-control study. Therefore, a selection bias could exist and may interfere with the interpretation of the results, although all patients who underwent SRS for the first time during the study period were included. The second factor that could affect the results concerns the quality of follow-up data. Because this study is not a prospective study, there may have been lost or uncollected follow-up data. Data regarding mortality were collected from the National Health Insurance Corporation of the Republic of Korea, to which all Korean people belong. Therefore, data regarding mortality should be accurate, even in the patients denied further treatments after SRS.
Conclusions
Patients with more than 15 metastatic brain lesions were found to have faster development of new lesions in the brain than patients who had fewer lesions. This finding may be due to the biological properties of the primary lesions, including a greater tendency to disseminate hematogenously, especially to the brain, or a higher probability of missed or invisible lesions (microscopic metastases) on stereotactic MR images. However, mean survival times after SRS were not statistically different, regardless of the number of brain metastases. Given the findings obtained in this study, SRS may be an effective and safe treatment option for local control of metastatic lesions and for improving survival times in patients with multiple metastatic brain lesions, even in those patients harboring more than 15 metastatic brain lesions, who may have early and easily detectable new brain lesions fol lowing SRS. 
